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Transitional cell carcinoma of bladder (TCCB) is the 
most common malignancy of the genitourinary system. 
Despite the use of the current multimodality approach 
to treatment of TCCB, the patients with the disease have 
a very high recurrency rate [1–3]. Therefore, the early 
detection of new or recurrent TCCB lesions is crucial 
for successful treatment and favorable prognosis. 
Currently, diagnosis and monitoring of TCCB is based 
on cystoscopy, combining the additional information 
provided by urinary cytology. Despite their great clinical 
utility, these diagnostic methods still have some limita-
tions mainly related to their sensitivity. Accordingly, 
alternative methods are urgently required. An objective 
marker detection that is not based only on morphologic 
criteria should have been established [4].
An ideal cancer marker should be objective, noninva-
sive, easy to administer and interpret, and possess high 
sensitivity and specificity. Bladder tumor antigen (BTA), 
fluorescence in situ hybridization (FISH), nuclear matrix 
protein-22 (NMP22) and human telomerase reverse 
transcriptase (hTERT) have been developed for monito-
ring patients with TCCB [5-6], and have been approved 
for clinical use, but their sensitivity depends on tumor 
diffe rentiation. Regular cystoscopic monitoring thus 
continues to be the standard in tumor surveillance.
Cytokeratins (CKs) are differentiation intermediate 
filament proteins, which constitute the cytoskeleton 
of epithelial cells. More than 20 different CKs are 
known, and are divided into types I and II based on 
sequence homology [7]. Moll et al. [8] used an im-
munohistochemistry technique to measure expression 
of a new cytokeratin 20 (CK20) which is expressed in 
gastrointestinal epithelium, uroepithelial cells from 
patients with urothelial cancer and Merkel cells, how-
ever, normal urothelial cells do not express the CK20 
gene. These findings suggest that CK20 expression 
possibly may serve as a specific marker for detecting 
urothelial cancer cells [9–10].
Because of its high sensitivity, real-time polymerase 
chain reaction (RT-PCR) based on the amplification of 
cell type-specific mRNA have been increasingly used 
to detect cancer marker [11–12]. In the present study 
we established a rapid quantitative method for detec-
tion of CK20 mRNA level in urine samples by RT-PCR 
on the LightCycler, investigated the diagnostic signifi-
cance of CK20 mRNA quantification in TCCB patients, 
and examined whether CK20 gene expression corre-
lates with the TCCB clinicopathologic features (tumor 
stage and grade).
MATERIALS AND METHODS
Patients. In the current work, urine samples 
of 60 patients with histologically proved TCCB and 
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20 patients with non-cancer urological diseases 
(bladder benign tumor, cystitis glandularis, ureteritis 
and urinary tract infection) treated at the First Affilia-
ted Hospital of Chongqing Medical University during 
September 2007 to October 2008 were examined. The 
study also included 15 healthy volunteers. TCCB cases 
were staged and graded pathologically according to 
the International Union Against Cancer 1997 TNM and 
WHO classifications (Table 1). All patients signed a 
consent form approved by the Committee on Human 
Rights in Research of our institution.
Table 1. Characteristics of patients with transitional cell carcinoma, non-
cancer urological diseases and control group of healthy volunteers
Group description Number of cases
TCCB patients (range 35–85 years) 60
Male-to-female ratio 46 : 14
Stage
pTis / pTa 18
pT1–2 32
pT3–4 10
Grade
1 28
2 20
3 12
Urological non-cancer diseases (range 16–78 years) 20
Male-to-female ratio 13 : 7
Healthy volunteers (range 20–40 years) 15
Male-to-female ratio 10 : 5
Sample preparation. First spontaneously voided 
urine (150–200 ml) was obtained from all patients and 
controls, enrolled in the study, divided by 50 ml for 
conventional cytological and nuclear matrix protein 22 
(NMP22) examination. The remaining volume imme-
diately was centrifuged at 800 g for 10 min at 4 °C to 
collect intact exfoliated cells for RT-PCR. The pellets 
were stored at –80 °C for further use.
Cytological and NMP22 examination. 48 ml 
of urine sample was centrifuged at 800 g; pellet was 
stained by hematoxilin/eosin and studied by light mic-
roscopy. 2 ml of urine sample was dripped into the 
sampling bottle, which contained specially stabilized 
reagent, and then centrifuged at 1000 r/min for 15 min. 
The supernatant was tested with NMP22 special ELISA 
kits (Matritech Inc., USA).
Design of the RT-PCR. The cDNA sequences 
were from Genbank: NM-019010. The regions for prim-
ers and probe were chosen based on the conserved 
areas; a 96-bp fragment of CK20 encoding mRNA 
was amplified from the cDNA (Table 2). Plasmid DNA 
standards for CK20 were diluted into eight (range 102 
to 109 copies/µl) and analyzed using an ABI 7000 (ABI, 
USA) sequence detection system and SDS software, 
A standard curve was constructed by the crossover 
point (CT).The CK20 mRNA value in each sample was 
calculated from this calibration curve.
Table 2. Primers and probe used for CK20 RT-PCR
F/R Primer sequence
Forward TTGAAGAGCTGCGAAGTCAGAT
Reverse TGAAGTCCTCAGCAGCCAGTT
Taqman probe FAM-TCAACTGCAAAATGCTCGGTGTGTCC-TAMRA
RNA extraction and cDNA synthesis. Total RNA 
was extracted from urine samples using a commercial-
ly available RNA extraction kit (Trizol, Takara, Japan) 
according to the manufacturer’s instructions. RNA 
concentrations were determined by spectrophoto-
metric analysis at 260 nm wavelength. Then reversely 
transcribed with a primescriptTM RT Reagent kit (Ta-
kara, Japan) : 5 × primescript buffer : 4 µl, primescript 
RT enzyme mix I : 1 µl, oligo dT primer (50 µM) × 1 : 
1 µl, random 6 mers (100 µM) × 1 : 1 µl, total RNA : 4 µl 
(50 ng), RNase free ddH2O : 9 µl, total volume : 20 µl. 
RT reactions were performed for 37 °C 15 min, 85 °C 
5 s. cDNA was stored at –20 °C for further PCR.
RT-PCR analysis of CK20 mRNA expression 
level in urine samples. The RT-PCR reactions were 
performed in 25 µl volumes containing 10 × PCR buffer : 
2.5 µl; MgCl2 (25 mmol/l) : 3.5 µl; dNTPs (2.5 mmol/l) : 
2 µl, Taq polymerase (5 U/µl): 0.35 µl; forward primer 
(10 pmol/µl) : 2.2 µl; reverse primer (10 pmol/µl) : 2.2 µl; 
Taqman probe (10 pmol/µl) : 2.2 µl; cDNA: 2 µl; ddH2O : 
8.05 µl; cycling parameters included 40 cycles of 5 min 
each at 95 °C, 30 s at 95 °C, and 70 s at 51 °C. Each 
run consisted of 8 external standards and a negative 
control. The amplified PCR products were run on 1% 
agarose gel, stained by ethidium bromide.
Statistical analysis. Statistical analysis was 
performed using SPSS 15.0 Statistical Package. 
Comparison of RT-PCR and cytological examination 
by the chi-square (X2) test, with p < 0.05 considered 
significant. The Kruskal-Wallis test was performed to 
analyze the significant variation among carcinoma, 
benign disease and control groups; CK20 values with 
reference to tumor staging and grading were analyzed 
by Kruskal-Wallis, p < 0.05 considered significant.
RESULTS
Evaluation of RT-PCR. To estimate the RT-PCR 
assay, using plasmid DNA control with 10 fold serial 
dilutions of known quantities from 101 to 1010 co pies/µl, 
amplifications of standard dilution series were then 
performed, a standard curve was constructed by 
plotting the crossover point, at which the signal in-
creased greater than the background level, against 
the log number of CK20 expression for each run. The 
RT-PCR assay that we developed showed high sensi-
tivity (102 copies/µl). The screening of urine samples of 
different for CK20 expression by RT-PCR has shown 
good specificity: CK20 expression has been registered 
only in urine samples from TCCB patients. The coeffi-
cient of variation (CV) value was 1.59% in batch assay, 
and 2.34% in a day to day assay, and wide range of 
linearity from 102 ~ 109 copies/µl (Fig. 1).
Cutoff value analysis by ROC curve. In present 
study, different cutoff values were used for discrimi-
nation between the presence or absence of CK20 in 
urine samples of TCCB patients. If after a predefined 
number of cycles no fluorescent signal was detected 
on amplification plots, the marker mRNA was assumed 
absent in the urine samples. The receiver operating 
characteristics (ROC) curve was used to estimate the 
cutoff value. The ROC curve for the predicted prob-
abilities of a positive assay (at 0.5 threshold) is shown 
in Fig. 2, while CT = 30, the area under the ROC curve 
is 0.896, there was best sensitivity and specificity.
Experimental Oncology 31, 43–47, 2009 (March) 45
500
400
300
200
100
0
-100
35
30
25
20
15
10
5
0
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
111213141516171819202122232425262728293031323334353637383940
a
b
Fig. 1. Standard curve of real time PCR for CK20. a, run profile 
of RT-PCR cycle number, wide range of linearity from eight 
external standards including 102 ~ 109 copies/µl; b, calibration 
curve for CK20 mRNA estimation constructed by plotting cycle 
number of crossover point against log, including 8 standards as 
shown in a. Relative CK20 mRNA values of unknown samples 
were calculated with reference to this curve
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Fig. 2. ROC curve for CK20 cutoff value. ROC curves were con-
structed by plotting sensitivity and 1-specificity corresponding 
to each cutoff value for CK20 mRNA
Comparison of sensitivity and specificity of 
urinary cytology and urinary CK20 mRNA value. 
Sensitivity and specificity of CK20 expression by RT-PCR 
in urine sample were 85% and 94.3% respectively, with 
a cutoff value of 30. Compared with urinary cytology 
(positive in 28 (46.7%), specificity 100%), RT-PCR had 
significantly higher sensitivity (p < 0.001); from the 32 cy-
tologically negative cases 23 were positive by RT-PCR, 
and only 9 were negative. All cytologically positive cases 
were RT-PCR positive (Fig. 3), which indicated improved 
accuracy of RT-PCR for TCCB diagnostics.
NMP22 and CK20 mRNA expression in urine 
samples. Detection CK20 expression had shown 
a higher sensitivity than detection of NMP22 expression 
(85% vs 78.3%, respectively), and higher specificity 
(94.3% vs 85% respectively). As reported in Table 3, 
sensitivity and specificity according to staging and grad-
ing of tumors was higher for CK20 than for NMP22 in 
the most cases, but in grade 2 tumors there was higher 
NMP22 expression level than shown for CK20.
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Fig. 3. Comparison of urinary cytology with CK20 results, RT-PCR 
positive (PCR [+]) or negative ([PCR [–]) was determined based on 
cutoff value 30. Cytology negative includes patients with classes 
1, 2 and 3 cytology, and positive includes classes 4 and 5
Table 3. Expression of CK20 and NMP22 mRNAs and tumor stage/grade
Sample No. CK20 NMP22Positive Negative Positive Negative
TCCB patients 60
Stage
pTis / pTa 18 14 (77.8%) 4 11 (61.1%) 7
pT1–2 32 28 (87.5%) 4 28 (87.5%) 4
pT3–4 10 9 (90%) 1 8 (80%) 2
Grade
1 28 23 (82.1%) 5 20 (71.4%) 8
2 20 17 (85%) 3 18 (90%) 2
3 12 11 (91.7%) 1 9 (75%) 3
Non-cancer diseases 20 2 18 (90%) 7 13 (65%)
Healthy volunteers 15 0 15 (100%) 2 13 (86.7%)
CK20 mRNA value in TCCB cases and control 
group. Different patients have significant CK20 expres-
sion variance. As it is shown on Fig. 4, the variance of 
CK20 mRNA expression in 9 urine samples from TCCB 
group analyzed by RT-PCR was 104 between the highest 
and lowest levels. Of the 60 cases of TCCB, mean CK20 
mRNA value was 27712.57 copies/µl (range 15.00 to 
46523.00), while in non-cancer urological disease 
group mean value was 74.45 copies/µl (0 to 328.00), 
and in control group, mean value was 8.47 copies/µl 
(0 to 35.00), and the variation was significant (p < 0.001, 
p < 0.001, respectively). The findings suggested that 
expression of CK20 is a marker of TCCB.
CK20 mRNA values and tumor staging and grad-
ing. Distribution of CK20 mRNA values by tumor grade 
and stage are shown on Fig. 5: mean CK20 mRNA value 
for 18 cases of noninvasive transitional cell carcinoma 
(pTis/pTa) was 20671.78 with individual data (range 15.00 
to 32659.00), and for 42 invasive transitional cell carci-
noma, including 32 cases pT1–2 was 29406.84 (48.00 to 
40834.00), and for 10 cases of pT3–4 was 35585.30 (86.00 
to 46523.00). Mean CK20 mRNA values for histological 
tumor grades 1, 2 and 3 were: 21901.89 (range 15.00 to 
40286.00, n = 28), 30985.45 (66.00 to 40834.00, n = 20), 
and 35716.00 (48.00 to 46523.00, n = 12), respectively. 
There was a statistically significant variation in G1 vs G2 
(p = 0.016), while G2 vs G3 had no statistically significant 
variation; there was a statistically significant variation in 
Tis/Ta vs T1–2 (p = 0.022), while T1–2 vs T3–4 had no statisti-
cally significant variation. These findings suggested cor-
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relation between CK20 and the clinicopathologic features 
(tumor stage and grade) of TCCB.
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Fig. 4. CK20 mRNA expression in 9 urine samples from TCCB 
group analyzed by RT-PCR and 1% agarose gel. a, amplification 
curve of urine samples CK20 expression via RT-PCR; b, RT-PCR 
products resolved in 1% agarose gel: M: marker DL2000, 1 ~ 7, 
9: CK20 RT-PCR product (+), 8: CK20 RT-PCR product (–). Dif-
ferent samples had different CK20 expression values
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Fig. 5. CK20 expression value and tumor staging and grading. 
CK20 expression increased gradually, G1 was significantly dif-
ferent from G2 (p = 0.016); Tis/Ta was significantly different from 
T1–2 (p = 0.022)
DISCUSSION
Cystoscopy is still considered the gold standard for 
the diagnosis and follow-up of TCCB, but it is invasive. 
Voided urine cytology is the most common noninvasive 
technique for detecting bladder cancer and has high 
specificity, however, it has poor sensitivity. Thus, detec-
tion of urine markers, which have sufficient sensitivity 
and specificity, and may be used as diagnostic and 
surveillance protocols of TCCB [13]. CK20 are inter-
mediate filaments expressed in epithelial cells, early 
immunological, and Northern blot studies found that 
CK20 expression was restricted primarily to gastrointes-
tinal tissue, transitional cell carcinoma, and Merkel cells 
[8]. Due to significantly higher expression in urothelial 
tumors in comparison with clinical controls including 
urological benign diseases and healthy volunteers, 
CK20 mRNA in urine of patients with TCCB is potentially 
useful urinary marker with diagnostic value [14–16].
Traditional PCR assays had been reported for the 
detection of CK20 mRNA, Rotem D et al. detected CK20 
expression of TCCB by traditional PCR, 86.7% of TCCB 
patients was positive, and only 3.3% of healthy volun-
teers were positive (specificity 96.7%), but traditional 
PCR depended on end point data collection, therefore 
susceptible to large variations that determine the 
outcome of every single reaction during PCR [17–19]. 
To overcome these problems, we established a new 
quantitative detection method for free cancer cells in the 
urine. Real-time PCR assays to quantify CK20 mRNA 
was performed with the use of total RNA extracted from 
the urine samples, and primers and hybridization probe 
specific for CK20.PCR product was measured during 
the exponential phase of PCR to eliminate the effect 
of large variations. To avoid cross-contamination, the 
analysis was divided into three separate work areas: 
(1) a plasmid DNA extraction area; (2) a master mix 
area for diluting and preparing reagent mixes; (3) and 
a RT-PCR reaction area. The working surfaces and 
equipment were kept sterile; all reagents were divided 
into specific storage [12]. With a cutoff value of CT = 30, 
CK20 mRNA sensitivity and specificity were 85% and 
94.3%, respectively. False-positive results were no lon-
ger obtained in the healthy volunteer group, but in 2 of 
20 patients in the non-cancer urological disease group 
with cystitis. These findings suggest that real-time PCR 
provides a rapid quantitative tool allowing appropriate 
diagnostic for TCCB.
In the present study, we determined cutoff value 
by the ROC curve that was constructed by plotting 
the sensitivity and specificity according to each cutoff 
value for CK20 mRNA. In all studies, additional statis-
tical criteria were explored to dichotomize between 
positive and negative urine samples. While CT = 30, 
there were the 95% confidence interval or the 99% 
percentile of log-normal distribution [14].
In the present study, we aimed to compare results of 
conventional urinary cytology and quantitative real-time 
PCR for diagnosis of TCCB. Our results demonstrated 
that using the best cutoff point determined by the ROC 
curve, the positivity rate of real-time PCR was significantly 
higher than that of urinary cytology. Of the 32 cytologi-
cally negative cases 23 were positive by real time PCR. 
These findings suggested that first, CK20 mRNA was 
positive but urine cytology was negative since some 
urine samples contain very low number of cancer cells, 
which may be insufficient for cytological examination but 
enough for detection of CK20 mRNA by the more sensi-
tive RT-PCR methods; second, RT-PCR false-negative 
results may be explained by negative or low expression 
of CK20 in transitional cell carcinoma cells.
The nuclear matrix is a RNA-protein network for-
ming the structural framework of the nucleus. Proteins 
that bind to RNA in the matrix are called nuclear ma-
trix proteins (NMPs). NMP22 was previously used as 
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a cancer-specific marker for TCCB. NMP22 specific 
ELISA kits are available for clinic application [20]. In 
this study, we compared CK20 and NMP22 expres-
sion for diagnose of TCCB. As the result, CK20 de-
tection has shown higher sensitivity and specificity. 
However, some patients yet could not be diagnosed 
only dependent on CK20 detection. The simultaneous 
evaluation of the two tumor markers gave us some 
benefits. Therefore, to find a proper combination of 
the available tumor markers for diagnosis of bladder 
cancer we should also consider the feasibility of each 
method in clinical practice.
The mean value of urinary CK20 mRNA was sig-
nificantly elevated in TCCB group compared to non-
cancer and control groups (p < 0.001). Interestingly, 
these finding were similar to the research of Inoue et 
al. [21] that CK20 mRNA values in the carcinoma group 
(mean 35,850) were significantly higher than non-
cancer (171) and control groups (4.55, p < 0.0001 and 
< 0.0001, respectively). The study of urine samples of 
60 cancer patients showed CK20 value varied signifi-
cantly between patients: range from 0 ~ 50 000 copies. 
Also, we found that CK20 value differs significantly 
between early stage tumors (between Tis/Ta and T1–2, 
G1 and G2), but not in advanced tumors (between T1–2 
and T3–4, G2 and G3).
In conclusion, our studies demonstrated that 
urine CK20 mRNA may serve as a marker of TCCB. 
The obtained data have suggested that quantitative 
RT-PCR of CK20 is more sensitive method for detec-
tion of transitional cell carcinoma cells in the urine 
than conventional cytology and detection of NMP22 
expression, and simultaneous application of both 
CK20 and NMP22 markers is even more effective. The 
Light Cycler system allows rapid convenient amplifica-
tion and on-line data analysis, making it applicable for 
routine assays in clinical practice.
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